 BioCryst Pharmaceuticals Inc NASDAQ: BCRX has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria PNH. REDEEM-1 will compare the efficacy and safety of BCX9930 monotherapy versus C5 inhibitor in approximately 81 PNH patients. 